Rocket Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
18.7%projected annual EPS growth
Analyst Coverage
11analysts covering
FY Revenue (est.)
$1.1Mnext fiscal year
FY EPS (est.)
-$0.11next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| RP-A501 Danon Disease Program Update | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash Runway (Years) Quarterly2.0Target: Extend beyond 2028
Pivotal Phase 2 RP-A501 Patient Enrollment Quarterly9.0
Watch Items
- RP-A501 Danon Disease Pivotal Phase 2 Trial Dosing and SafetyTrigger: Any serious adverse events (SAEs) or thrombotic microangiopathy (TMA) occurrences under the recalibrated dose of 3.8 x 10¹³ GC/kgAction: Immediate clinical review, potential protocol adjustment, or regulatory reporting to prevent further clinical holds.
- KRESLADI Commercial Launch and Pricing StrategyTrigger: Launch delay beyond Q4 2026 or failure to secure favorable payer reimbursementAction: Re-evaluate commercial infrastructure, engage in outcomes-based reimbursement negotiations, and adjust sales guidance.
Research as of 19 Jun 2026